DDInter1331 DDInter1658
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Olodaterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Olodaterol may lead to a major life threatening interaction when taken with Cocaine